Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 0 | 0 | 0 | 12,000 | 0 |
| Gross Profit | N/A | N/A | N/A | 12,000 | N/A |
| Operating Expenses | 9,291 | 12,847 | 10,422 | 14,364 | 18,103 |
| Operating Income | -9,291 | -12,847 | -10,422 | -2,364 | -18,103 |
| Interest Expense | 666 | 998 | 1,132 | 1,128 | 1,075 |
| Other Income | 38 | 372 | 1,872 | 1,665 | 72 |
| Pre-tax Income | -9,920 | -13,473 | -9,681 | -1,827 | -19,106 |
| Income Tax | N/A | 53 | 28 | 58 | -7 |
| Net Income Continuous | -9,920 | -13,526 | -9,709 | -1,886 | -19,099 |
| Net Income | $-9,920 | $-13,512 | $-9,709 | $-1,886 | $-19,112 |
| EPS Basic Total Ops | -4.24 | -5.84 | -4.48 | -0.88 | -10.32 |
| EPS Basic Continuous Ops | -4.25 | -5.77 | -4.52 | -0.92 | -10.30 |
| EPS Diluted Total Ops | -4.24 | -5.84 | -4.48 | -0.88 | -10.32 |
| EPS Diluted Continuous Ops | -4.25 | -5.77 | -4.52 | -0.92 | -10.30 |
| EPS Diluted Before Non-Recurring Items | -10.32 | -6.24 | -4.48 | -0.88 | -10.32 |
| EBITDA(a) | $-9,291 | $-12,847 | $-10,422 | $-2,364 | $-18,103 |